CJC-1295 and IGF-1 LR3 Together: What the Research Literature Covers

Answer first: no published study combined them

Search queries such as "can you stack IGF-1 LR3 with CJC-1295" assume a body of combination research that does not appear to exist. Across the peer-reviewed papers reviewed for this page, no clinical trial, animal experiment or case series administered CJC-1295 and IGF-1 LR3 together. The two compounds sit in almost entirely separate literatures. CJC-1295 was characterised as a long-acting growth-hormone-releasing factor analog in rats (PMID 15817669) and then in an early-phase human study (PMID 16352683). Long R3 IGF-1 appears chiefly in animal physiology research (PMID 39679943, PMID 37114757) and in recombinant protein production work (PMID 37261455). Because no study paired them, the literature contains no data on combined pharmacology, combined effects or combined risks. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, medication or laboratory compounds.

What CJC-1295 is, as described in the literature

CJC-1295 belongs to the growth-hormone-releasing hormone (GHRH) analog family. The molecule is built on the biologically active 1–29 fragment of human growth hormone-releasing factor. In the foundational report, researchers described hGRF(1–29)–albumin bioconjugates that activated the GRF receptor on the anterior pituitary in rats, and identified CJC-1295 as the long-lasting analog in that series (PMID 15817669). The design logic in that paper was durability: by covalently attaching the peptide to circulating albumin, the conjugate resisted the rapid clearance that limits native GHRH.

Mechanistically, this places CJC-1295 upstream in the growth hormone axis. It does not supply growth hormone or IGF-1 directly. It signals the pituitary to release endogenous growth hormone, which then acts on the liver and other tissues, where IGF-1 is produced. Any IGF-1 rise observed after CJC-1295 administration is therefore a downstream, secondary consequence of pituitary stimulation rather than a direct effect of the injected molecule.

What the human trial reported

The 2006 study in The Journal of Clinical Endocrinology and Metabolism examined single escalating subcutaneous doses in healthy adults, spanning roughly 30 to 250 µg/kg, followed by multiple-dose administration. Researchers reported that mean plasma growth hormone concentrations rose approximately 2- to 10-fold for six days or more after a single dose, and that mean IGF-1 concentrations rose about 1.5- to 3-fold, remaining elevated for roughly 9 to 11 days (PMID 16352683). The study's central observation was duration: a single administration produced a prolonged, rather than pulse-like, elevation of both hormones. That trial was small and early-phase, and it measured hormone pharmacodynamics rather than clinical outcomes such as body composition, strength or injury recovery.

Downstream markers and detection work

A follow-up analysis of normal adult subjects looked at what activation of the GH/IGF-1 axis by CJC-1295 did to the serum proteome. Researchers reported measurable changes in serum protein profiles accompanying that axis activation, framing the findings partly in the context of biomarker and anti-doping detection (PMID 19386527). Separate analytical literature reflects the compound's appearance outside clinical settings: one report described the identification of CJC-1295 in an unknown pharmaceutical preparation submitted for analysis (PMID 21204297), and another described an LC-MS/MS method developed to confirm CJC-1295 abuse in equine plasma samples (PMID 30938069). Those papers are about detection and product identity, not about efficacy.

What IGF-1 LR3 is, as described in the literature

IGF-1 LR3 — written in journals as "long R3 IGF-1" or "LR3 IGF-1" — is an engineered analog of insulin-like growth factor 1. It carries an amino-acid substitution at position 3 and an N-terminal extension, modifications intended to reduce binding to IGF binding proteins and extend the molecule's persistence relative to native IGF-1. Unlike CJC-1295, it acts downstream: it is a receptor ligand, supplied directly rather than released by the pituitary.

Much of the LR3 literature is production-oriented rather than clinical. One 2023 paper reported recombinant expression of both IGF-1 and LR3 IGF-1 fused with xylanase in the yeast Pichia pastoris, work aimed at making these proteins more practical to manufacture (PMID 37261455). That framing matters for interpretation: LR3 IGF-1 is widely handled as a laboratory reagent and cell-culture supplement, and papers about it often concern expression systems, stability or experimental physiology rather than human therapy.

Animal findings researchers reported

Three animal studies illustrate what the published record actually contains. In late-gestation growth-restricted fetal sheep, researchers reported that IGF-1 LR3 did not promote growth — a negative result, published in 2025 (PMID 39679943). A related sheep experiment examined glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion and reported that secretion was attenuated during the infusion, but that the effect did not persist in isolated islets studied afterwards (PMID 37114757). In a neurological model, intranasal long R3 IGF-1 in male 5XFAD mice promoted amyloid plaque remodeling in the cerebral cortex but failed to preserve cognitive function (PMID 39610283). None of these studies involved athletic performance, muscle hypertrophy in healthy adults, or human volunteers.

Side-by-side: two different literatures

Why the question keeps coming up

Three factors appear to drive the query, and none of them is published combination evidence.

• Mechanistic symmetry. One compound acts on the pituitary, the other on the IGF-1 receptor. That arrangement invites the intuition that upstream and downstream inputs might be additive. Intuition of that kind is a hypothesis, not a finding; the growth hormone axis is regulated by feedback loops that the published single-compound studies were not designed to model jointly.
• Online information circulation. A qualitative netnography of female use of CJC-1295 analysed how information about the compound spread through internet forums, describing self-reported practices and the language communities used (PMID 26771670). Studies of this kind document what people discuss online; they do not evaluate whether the practices described are effective or safe.
• Availability outside clinical channels. The presence of CJC-1295 in an unlabelled pharmaceutical preparation (PMID 21204297) and the development of doping-control assays for it in animals (PMID 30938069) both indicate that the molecule circulated in settings without clinical supervision. Compounds that circulate that way accumulate informal protocols faster than they accumulate trials.

Safety Signals and Adverse Events: What Studies Report

The relevant safety picture is defined as much by what was not measured as by what was. The rat characterisation work and the early-phase human trial were designed around hormone pharmacodynamics — receptor activation, growth hormone release and IGF-1 duration — rather than long-term tolerability, and the human trial was small (PMID 15817669, PMID 16352683). Studies of that size and duration cannot detect uncommon harms.

On the IGF-1 LR3 side, the most concrete physiological signal in the reviewed papers concerned glucose metabolism: researchers reported that glucose-stimulated insulin secretion was attenuated during an acute infusion in fetal sheep, with the change not persisting in isolated islets (PMID 37114757). Two other studies reported absence of the intended benefit — no growth promotion in growth-restricted fetal sheep (PMID 39679943) and no preservation of cognitive function in a mouse model despite plaque remodeling (PMID 39610283). Negative findings of this kind are part of the safety conversation because they show that a plausible mechanism did not translate into the expected outcome in the species tested. For the combination specifically, there is no adverse-event data at all, because no combination study was conducted.

Product identity and regulatory context

Neither compound is an approved medicine under the names used in peptide discussions. Recombinant human IGF-1 exists as a prescription product for specific diagnosed conditions, but that is a different molecule from the LR3 analog described in the research literature. LR3 IGF-1 appears in journals in research and manufacturing contexts (PMID 37261455), and materials sold as research-use-only are not evaluated for human administration. CJC-1295 similarly has no marketing authorisation; the analytical paper that identified it in an unknown preparation illustrates that labelling on non-pharmaceutical material cannot be assumed to reflect contents (PMID 21204297). Both compounds also fall within anti-doping frameworks, which is why detection methods were developed for them (PMID 30938069, PMID 19386527).

Open questions the literature leaves unanswered

1. Whether adding a direct IGF-1 receptor ligand alters the growth hormone and IGF-1 dynamics that were reported after CJC-1295 alone (PMID 16352683) — untested.
2. Whether the glucose-handling signal seen with IGF-1 LR3 in fetal sheep (PMID 37114757) has any counterpart in adult humans — untested.
3. Whether any outcome that peptide communities associate with these compounds has been measured in a controlled human study of either one, let alone both — not in the papers reviewed here.

Until such studies exist, the honest summary is narrow: the literature describes two molecules with distinct mechanisms, one small early-phase human dataset, several animal experiments including negative results, and no combination research whatsoever. Anyone weighing questions in this area is doing so in the absence of combination evidence, which is itself the most important fact on the page.

References

• Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog (Endocrinology, 2005)
• Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (The Journal of Clinical Endocrinology and Metabolism, 2006)
• Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects (Growth Hormone & IGF Research, 2009)
• Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation (Drug Testing and Analysis, 2010)
• Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions (Substance Use & Misuse, 2016)
• A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS (Drug Testing and Analysis, 2019)
• Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris (Applied Microbiology and Biotechnology, 2023)
• Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets (Journal of Developmental Origins of Health and Disease, 2023)
• Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice (Journal of Alzheimer's Disease, 2025)
• IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep (American Journal of Physiology. Endocrinology and Metabolism, 2025)